Off-Label Therapies for COVID-19-Are We All In This Together?

被引：21

作者：

Alpern, Jonathan D. ^{[1
,2
,3
]}

Gertner, Elie ^{[1
,3
,4
]}

机构：

[1] HealthPartners Inst, Bloomington, MN 55425 USA

[2] HealthPartners, Infect Dis Sect, St Paul, MN 55107 USA

[3] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA

[4] HealthPartners, Sect Rheumatol, St Paul, MN USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 108卷 / 02期

关键词：

D O I：

10.1002/cpt.1862

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) continues to spread rapidly outside of mainland China. As of April 6, 2020, there are over 300,000 cases and 10,000 deaths in the United States. Effective therapies for the novel coronavirus are urgently needed and over 200 clinical trials are now underway across the globe. Recognizing the need for robust randomized control trials, the World Health Organization (WHO) recently organized a multinational randomized trial-the SOLIDARITY trial-to study the effect of drugs that have been identified as promising based on in vitro data and the early clinical experience with coronavirus disease 2019 (COVID-19): remdesivir, lopinavir, and ritonavir; lopinavir and ritonavir + interferon; and chloroquine or hydroxychloroquine (Plaquenil).

引用

页码：182 / 184

页数：3

共 50 条

[1] Nonstandard and off-label therapies for psoriasis
Halverstam, Caroline P.
Lebwohl, Mark
[J]. CLINICS IN DERMATOLOGY, 2008, 26 (05) : 546 - 553
[2] The COVID-19 Pandemic: We Are All in This Together
Momplaisir, Florence
[J]. CLINICAL INFECTIOUS DISEASES, 2020, 71 (15) : 892 - 893
[3] COVID-19 and inequality: are we all in this together?
Shehzad Ali
Miqdad Asaria
Saverio Stranges
[J]. Canadian Journal of Public Health, 2020, 111 : 415 - 416
[4] COVID-19 and inequality: are we all in this together?
Ali, Shehzad
Asaria, Miqdad
Stranges, Saverio
[J]. CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2020, 111 (03): : 415 - 416
[5] Applying CiPA paradigm for assessing proarrhythmia risk of Covid-19 current off-label used therapies
Delaunois, Annie
Hebeisen, Simon
Gryshkova, Vitalina
Lushbough, Isabel
Passini, Elisa
Trovato, Cristian
Rodriguez, Blanca
Valentin, Jean-Pierre
[J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2021, 111
[6] Off-label use of targeted therapies in oncology
Leveque, Dominique
[J]. WORLD JOURNAL OF CLINICAL ONCOLOGY, 2016, 7 (02): : 253 - 257
[7] Off-label therapy targeting pathogenic inflammation in COVID-19
Romani, Luigina
Tomino, Carlo
Puccetti, Paolo
Garaci, Enrico
[J]. CELL DEATH DISCOVERY, 2020, 6 (01)
[8] Evaluating interest in off-label use of disinfectants for COVID-19
Rivera, Jessica Malaty
Gupta, Shagun
Ramjee, Divya
El Hayek, Ghinwa Y.
El Amiri, Nisrine
Desai, Angel N.
Majumder, Maimuna S.
[J]. LANCET DIGITAL HEALTH, 2020, 2 (11): : E564 - E566
[9] Cardiac adverse reactions with off-label Covid-19 treatments
[J]. Reactions Weekly, 2020, 1806 (1) : 10 - 10
[10] ADRs due to off-label use of hydroxychloroquine for COVID-19
[J]. Reactions Weekly, 2022, 1907 (1) : 3 - 3

← 1 2 3 4 5 →